Exact Sciences Corp. (NASDAQ:EXAS)’s share price shot up 6.5% during mid-day trading on Thursday . The stock traded as high as $20.79 and last traded at $20.72, with a volume of 3,272,490 shares changing hands. The stock had previously closed at $19.45.

EXAS has been the topic of several research analyst reports. Roth Capital restated a “hold” rating and set a $15.00 target price (up from $11.00) on shares of Exact Sciences Corp. in a research report on Monday, August 1st. Robert W. Baird restated an “outperform” rating and set a $18.00 target price on shares of Exact Sciences Corp. in a research report on Sunday, July 31st. BTIG Research restated a “buy” rating and set a $20.00 target price on shares of Exact Sciences Corp. in a research report on Sunday, July 31st. Zacks Investment Research upgraded shares of Exact Sciences Corp. from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a research report on Friday, July 29th. Finally, Craig Hallum boosted their target price on shares of Exact Sciences Corp. from $18.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, July 27th. Seven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $15.54.

The stock’s 50-day moving average price is $14.82 and its 200-day moving average price is $8.76. The stock’s market cap is $2.08 billion.

Exact Sciences Corp. (NASDAQ:EXAS) last posted its quarterly earnings data on Tuesday, July 26th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.09. During the same period in the prior year, the firm posted ($0.44) EPS. The business earned $21.20 million during the quarter, compared to analyst estimates of $18.54 million. Exact Sciences Corp.’s revenue for the quarter was up 161.7% compared to the same quarter last year. Equities research analysts predict that Exact Sciences Corp. will post ($1.80) earnings per share for the current year.

In other Exact Sciences Corp. news, insider Graham Peter Lidgard sold 7,383 shares of the business’s stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $14.82, for a total value of $109,416.06. Following the transaction, the insider now owns 227,592 shares of the company’s stock, valued at $3,372,913.44. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Katherine S. Zanotti acquired 3,380 shares of Exact Sciences Corp. stock in a transaction on Wednesday, August 3rd. The stock was acquired at an average cost of $17.93 per share, for a total transaction of $60,603.40. Following the purchase, the director now owns 105,927 shares of the company’s stock, valued at approximately $1,899,271.11. The disclosure for this purchase can be found here.

A hedge fund recently raised its stake in Exact Sciences Corp. stock. US Bancorp DE raised its position in Exact Sciences Corp. (NASDAQ:EXAS) by 2.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 229,594 shares of the company’s stock after buying an additional 5,109 shares during the period. US Bancorp DE owned about 0.24% of Exact Sciences Corp. worth $2,119,000 at the end of the most recent reporting period.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.